- Home
- IMUX vs APLT Comparison
IMUX vs APLT Comparison
Compare IMUX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- APLT
- Stock Information
- Founded
- IMUX 2016
- APLT 2016
- Country
- IMUX United States
- APLT United States
- Employees
- IMUX N/A
- APLT N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- APLT Health Care
- Exchange
- IMUX Nasdaq
- APLT Nasdaq
- Market Cap
- IMUX 90.4M
- APLT 63.6M
- IPO Year
- IMUX N/A
- APLT 2019
- Fundamental
- Price
- IMUX $0.79
- APLT $0.42
- Analyst Decision
- IMUX Strong Buy
- APLT Buy
- Analyst Count
- IMUX 5
- APLT 6
- Target Price
- IMUX $7.50
- APLT $6.10
- AVG Volume (30 Days)
- IMUX 1.3M
- APLT 883.6K
- Earning Date
- IMUX 11-06-2025
- APLT 11-06-2025
- Dividend Yield
- IMUX N/A
- APLT N/A
- EPS Growth
- IMUX N/A
- APLT N/A
- EPS
- IMUX N/A
- APLT N/A
- Revenue
- IMUX N/A
- APLT $121,000.00
- Revenue This Year
- IMUX N/A
- APLT N/A
- Revenue Next Year
- IMUX N/A
- APLT $5,931.24
- P/E Ratio
- IMUX N/A
- APLT N/A
- Revenue Growth
- IMUX N/A
- APLT N/A
- 52 Week Low
- IMUX $0.56
- APLT $0.30
- 52 Week High
- IMUX $2.11
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- IMUX 42.07
- APLT 38.92
- Support Level
- IMUX $0.74
- APLT $0.43
- Resistance Level
- IMUX $0.90
- APLT $0.46
- Average True Range (ATR)
- IMUX 0.06
- APLT 0.03
- MACD
- IMUX -0.00
- APLT -0.01
- Stochastic Oscillator
- IMUX 25.02
- APLT 0.35
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.